PT71436B - Process for preparing pharmaceutical compositions - Google Patents

Process for preparing pharmaceutical compositions

Info

Publication number
PT71436B
PT71436B PT71436A PT7143680A PT71436B PT 71436 B PT71436 B PT 71436B PT 71436 A PT71436 A PT 71436A PT 7143680 A PT7143680 A PT 7143680A PT 71436 B PT71436 B PT 71436B
Authority
PT
Portugal
Prior art keywords
pharmaceutical compositions
preparing pharmaceutical
preparing
compositions
pharmaceutical
Prior art date
Application number
PT71436A
Other languages
Portuguese (pt)
Other versions
PT71436A (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PT71436A publication Critical patent/PT71436A/en
Publication of PT71436B publication Critical patent/PT71436B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1277Processes for preparing; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT71436A 1979-06-22 1980-06-20 Process for preparing pharmaceutical compositions PT71436B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH586379 1979-06-22

Publications (2)

Publication Number Publication Date
PT71436A PT71436A (en) 1980-07-01
PT71436B true PT71436B (en) 1981-10-23

Family

ID=4300559

Family Applications (1)

Application Number Title Priority Date Filing Date
PT71436A PT71436B (en) 1979-06-22 1980-06-20 Process for preparing pharmaceutical compositions

Country Status (21)

Country Link
US (1) US4411894A (en)
EP (1) EP0021337B1 (en)
JP (1) JPS567714A (en)
KR (1) KR850001301B1 (en)
AR (1) AR230178A1 (en)
AT (1) ATE5508T1 (en)
AU (1) AU534959B2 (en)
CA (1) CA1173360A (en)
DE (1) DE3065818D1 (en)
DK (1) DK155172C (en)
ES (1) ES492676A0 (en)
FI (1) FI72875C (en)
HU (1) HU186296B (en)
IE (1) IE49615B1 (en)
IL (1) IL60326A (en)
MC (1) MC1336A1 (en)
NO (1) NO155226C (en)
NZ (1) NZ194047A (en)
PH (1) PH16795A (en)
PT (1) PT71436B (en)
ZA (1) ZA803567B (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59152348A (en) * 1983-02-19 1984-08-31 Kaken Pharmaceut Co Ltd Biphenylylpropionic acid ester derivative and its preparation
US5186941A (en) * 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
JPH0768117B2 (en) * 1983-05-06 1995-07-26 ベスター・インコーポレイテツド Vesicle formulation for controlled drug release
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
CA1237670A (en) * 1983-05-26 1988-06-07 Andrew S. Janoff Drug preparations of reduced toxicity
JPS601122A (en) * 1983-06-20 1985-01-07 Green Cross Corp:The Fat emulsion of biphenylylpropionic acid derivative
CA1264162A (en) * 1984-03-15 1990-01-02 Manfred Breuninger Glycerol ether phosphatides
JPS60208910A (en) * 1984-03-31 1985-10-21 Green Cross Corp:The Preparation of composite of hardly water-soluble drug and phospholipid
US4891208A (en) * 1985-04-10 1990-01-02 The Liposome Company, Inc. Steroidal liposomes
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
PT78628B (en) * 1984-05-02 1986-06-18 Liposome Co Inc Pharmaceutical composition with reduced toxicity
CA1264668C (en) * 1984-06-20 1990-01-23 Extrusion techniques for producing liposomes
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
CA1270198A (en) * 1984-08-08 1990-06-12 Marcel B. Bally Encapsulation of antineoplastic agents in liposomes
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
JPS61100518A (en) * 1984-10-22 1986-05-19 Ono Pharmaceut Co Ltd Lyophilized ribosome pharmaceutical preparation comprising dimyristoylphosphatidylcholine as main component
US4857319A (en) * 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
AU587600B2 (en) * 1985-01-11 1989-08-24 Regents Of The University Of California, The Method for preserving liposomes
US4753788A (en) * 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
CA1256372A (en) * 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
US5409704A (en) * 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
IL79114A (en) * 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes
US5622713A (en) * 1985-09-17 1997-04-22 The Regents Of The University Of California Method of detoxifying animal suffering from overdose
US4766046A (en) * 1985-09-27 1988-08-23 Liposome Technology, Inc. Stabilized liposome/amphotericin composition and method
US5041278A (en) * 1985-10-15 1991-08-20 The Liposome Company, Inc. Alpha tocopherol-based vesicles
IE58981B1 (en) * 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
US4861580A (en) * 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
SE8505047L (en) * 1985-10-25 1987-04-26 Nutritional Int Res Inst fat emulsion
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
US5252263A (en) * 1986-06-16 1993-10-12 The Liposome Company, Inc. Induction of asymmetry in vesicles
MX9203808A (en) * 1987-03-05 1992-07-01 Liposome Co Inc HIGH DRUG CONTENT FORMULATIONS: LIPID, FROM LIPOSOMIC-ANTINEOPLASTIC AGENTS.
US4950432A (en) * 1987-10-16 1990-08-21 Board Of Regents, The University Of Texas System Polyene microlide pre-liposomal powders
US4946683A (en) * 1987-11-18 1990-08-07 Vestar, Inc. Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes
JP2792702B2 (en) * 1988-10-05 1998-09-03 ネクスター・フアーマシユーテイカルズ・インコーポレイテツド Method for preparing liposomes with improved stability when dried
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
DK0555229T3 (en) * 1990-07-31 1996-08-19 Liposome Co Inc Accumulation of amino acids and peptides in liposomes
US5462740A (en) * 1993-09-17 1995-10-31 Athena Neurosciences, Inc. Rectally-administered, epileptic-seizure-inhibiting composition
US5840328A (en) * 1994-01-11 1998-11-24 The Liposome Company, Inc. Treatment using arachidonic acid metabolite and particulate formulations
JPH10508578A (en) * 1994-09-23 1998-08-25 ザ リポソーム カンパニー、インコーポレーテッド Method for producing a lyophilized liposome product
US6689370B1 (en) 1995-04-20 2004-02-10 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
FR2733151B1 (en) * 1995-04-20 1997-05-23 Seppic Sa THERAPEUTIC COMPOSITION COMPRISING AN ANTIGEN OR AN IN VIVO GENERATOR OF A COMPOUND COMPRISING AN AMINO ACID SEQUENCE
US6117432A (en) * 1995-04-20 2000-09-12 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
US20040208922A1 (en) * 1995-06-07 2004-10-21 The Regents Of The University Of California Method for loading lipid like vesicles with drugs or other chemicals
EP0855906B1 (en) * 1995-10-17 2008-02-20 Jagotec AG Insoluble drug delivery
GB9609779D0 (en) 1996-05-10 1996-07-17 Univ Bruxelles Freeze dried liposome encapsulated amphiphilic drug compositions and a process for the preparation thereof
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US5827532A (en) * 1997-01-31 1998-10-27 The Reagents Of The University Of California Method for loading lipsomes with ionizable phosphorylated hydrophobic compounds, pharmaceutical preparations and a method for administering the preparations
IT1289938B1 (en) * 1997-02-20 1998-10-19 Angelini Ricerche Spa PHARMACEUTICAL PREPARATION INCLUDING LYOPHYLIZED LIPOSOMES IN WHICH A HIGHLY WATER-INSOLUBLE ACTIVE SUBSTANCE IS ENCAPSULATED AND
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
ATE241363T1 (en) * 1998-02-11 2003-06-15 Rtp Pharma Corp COMBINATION PREPARATIONS CONTAINING UNSATURATED FATTY ACID AND STEROIDS FOR THE TREATMENT OF INFLAMMATION
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
CA2333648C (en) 1998-05-29 2008-10-21 Rtp Pharma Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
CN1221249C (en) 1998-08-19 2005-10-05 斯凯伊药品加拿大公司 Injectable aqueous dispersions of propofol
CA2349203C (en) 1998-11-20 2013-05-21 Rtp Pharma Inc. Dispersible phospholipid stabilized microparticles
EP1276465B1 (en) 2000-04-20 2014-03-12 Jagotec AG Improved water-insoluble drug particle process
US6653062B1 (en) * 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
CN100457090C (en) 2000-08-31 2009-02-04 斯凯伊药品加拿大公司 Milled particles
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
EP1355634B8 (en) * 2000-11-09 2009-03-04 Neopharm, Inc. Sn-38 lipid complexes and methods of use
TWI288000B (en) * 2001-02-22 2007-10-11 Rtp Pharma Inc Fibrate-statin combinations with reduced fed-fasted effects
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
AU2003296897A1 (en) * 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
KR100651728B1 (en) * 2004-11-10 2006-12-06 한국전자통신연구원 Compounds having anchoring group and electronic device including the same and methods for producing the same
CA2503087A1 (en) * 2005-03-30 2006-09-30 Medicure International Inc. Intravenous formulations of pyridoxal 5'-phosphate and method of preparation
ES2402823T3 (en) * 2006-06-01 2013-05-09 Institut De Cardiologie De Montreal Compound for use in the treatment of valve stenosis
ES2620478T3 (en) 2009-02-16 2017-06-28 Cerenis Therapeutics Holding Sa Mimetics of apolipoprotein A-I

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2081586A2 (en) * 1970-01-24 1971-12-10 Orsymonde Dehydrated pharmaceutical comps by - lyophilisation
JPS5186117A (en) * 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
IT1202370B (en) * 1976-07-12 1989-02-09 Hoffmann La Roche INJECTABLE SOLUTIONS IN WHICH THE EMOLITHIC LIFE OF NATURAL MICELLES TRAINING AGENTS IS AVOIDED BY THE ADDITION OF LIPOIDS AND RELATED PRODUCTS
DE2656333C2 (en) * 1976-12-13 1985-08-08 Karl Prof. Dr.med. 7302 Ostfildern Theurer Process for the production of liposomes which contain medicinal substances
GB1575343A (en) * 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
CH621479A5 (en) * 1977-08-05 1981-02-13 Battelle Memorial Institute

Also Published As

Publication number Publication date
DK155172C (en) 1989-09-18
PH16795A (en) 1984-02-28
ZA803567B (en) 1981-06-24
ES8104720A1 (en) 1981-05-16
KR830002327A (en) 1983-05-28
NZ194047A (en) 1982-09-14
NO155226C (en) 1987-03-04
CA1173360A (en) 1984-08-28
EP0021337A2 (en) 1981-01-07
DK155172B (en) 1989-02-27
KR850001301B1 (en) 1985-09-12
EP0021337B1 (en) 1983-12-07
IL60326A (en) 1983-09-30
ATE5508T1 (en) 1983-12-15
JPS567714A (en) 1981-01-27
MC1336A1 (en) 1981-04-21
US4411894A (en) 1983-10-25
EP0021337A3 (en) 1981-04-22
DE3065818D1 (en) 1984-01-12
IE49615B1 (en) 1985-10-30
FI801876A (en) 1980-12-23
AR230178A1 (en) 1984-03-01
PT71436A (en) 1980-07-01
DK266680A (en) 1980-12-23
FI72875B (en) 1987-04-30
NO155226B (en) 1986-11-24
FI72875C (en) 1987-08-10
ES492676A0 (en) 1981-05-16
HU186296B (en) 1985-07-29
AU5928980A (en) 1981-01-08
IL60326A0 (en) 1980-09-16
IE801281L (en) 1980-12-22
AU534959B2 (en) 1984-02-23
NO801863L (en) 1980-12-22

Similar Documents

Publication Publication Date Title
PT71436A (en) Process for preparing pharmaceutical compositions
DE3060129D1 (en) Tetrahydroisoquinoline compounds, process for preparing them and pharmaceutical compositions containing them
DE3064173D1 (en) Novel 20-0-acylmaytansinoids, process for their preparation and pharmaceutical compositions containing them
GB2122085B (en) A process for the preparation of activated pharmaceutical compositions
MY8500062A (en) 1,2,4-troazome deriovatives, process for preparing such compounds and pharmaceutical compositions containing them
PT68980A (en) Process for preparing surfactive compositions
DE3060861D1 (en) Monophosphonate compounds, process for their preparation and pharmaceutical compositions containing them
PT70927A (en) Process for preparing 9-aminoalkylfluorenes
PT71093A (en) Process for preparing oxytetracycline compositions
PT69207A (en) Process for preparing pharmaceutical formulations
PT72216A (en) Process for preparing toothpaste compositions
DE3061152D1 (en) Pyrazoloindazole derivatives and process for preparing the same and pharmaceutical compositions
GB2050833B (en) Pharmaceutical compositions and process for the preparation thereof
DE3061037D1 (en) Process for preparing dimethylaminosilanes
HUT36099A (en) Pharmaceutical compositions containing process for preparing 4-aroyl-imidazol-2-one derivatives
DE3060079D1 (en) Spiro-quinolylhydantoins, process for their preparation and pharmaceutical compositions thereof
DE3060089D1 (en) Process for preparing 1-amino-2-phenoxy-4-hydroxy-anthraquinone
IL60907A0 (en) Substituted quinoline-alkanecarboxylic acids,process for their preparation and pharmaceutical compositions containing them
PT72727A (en) Process for preparing pharmaceutical compositions
PT71126A (en) Process for preparing alkoxyalkylidenhydrazinopyridazines
PT75504A (en) Process for preparing pharmaceutical compositions
GB2058068B (en) Process for preparing 5-chloro-2-nitrophenol
DE3060850D1 (en) Process for preparing naphthalenesulphochloride
ZA80521B (en) Process for preparation of -lactam compounds
PT71697A (en) Process for preparing substituted trichloropropylureas andfungicidal compositions thereof